Afzal Nagani
Afzal Nagani publishes mostly in Organic Chemistry, Molecular Biology and Pharmacology, on topics such as Synthesis and biological activity, Computational Drug Discovery Methods and Cholinesterase and Neurodegenerative Diseases.
- World rank
- #2,055,638 of 7,710,434 ranked researchers
- Rank in India
- #35,799 of 280,097
- Works
- 25
- Citations
- 270
- Citations per work
- 10.8
What does Afzal Nagani research?
Afzal Nagani's work is mostly in Chemistry (45%), Biochemistry, Genetics and Molecular Biology (17%), Medicine (16%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Physical Sciences1352.6%
- Chemistry1144.9%
- Computer Science27.7%
- Life Sciences416.7%
- Health Sciences415.5%
- Medicine415.5%
- Everything else415.2%
- 1Organic Chemistry45% of their works
- 2Molecular Biology17% of their works
- 3Pharmacology10% of their works
- 4Computational Theory and Mathematics8% of their works
- 5Physiology3% of their works
- 6Oncology3% of their works
Research topics
- Synthesis and biological activity
- Computational Drug Discovery Methods
- Cholinesterase and Neurodegenerative Diseases
- Synthesis and Characterization of Heterocyclic Compounds
- Multicomponent Synthesis of Heterocycles
- Synthesis and Biological Evaluation
- Click Chemistry and Applications
- Biochemical and Molecular Research
Which keywords describe Afzal Nagani's research?
The keywords of their largest research topics: Medicinal Chemistry, Anticancer Agents, Heterocyclic Compounds, Tubulin Inhibitors, Vascular Targeting Agents, Drug Discovery, Molecular Docking and Biological Evaluation.
- Enzyme Regulation
- Copper-Catalyzed Cycloaddition
- Antimicrobial Activity
- Multicomponent Reactions
- Antimicrobial
- Acetylcholinesterase
- Drug Target Identification
- Biological Evaluation
- Drug Discovery
- Tubulin Inhibitors
- Anticancer Agents
- Medicinal Chemistry
- Heterocyclic Compounds
- Vascular Targeting Agents
- Molecular Docking
- Synthesis
- Virtual Screening
- Cholinesterase Inhibitors
- Green Chemistry
- Triazines
- Click Chemistry
- Quinoxaline
- Nucleotide Metabolism
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 23 words, with their numbers
- Medicinal Chemistry223 topics
- Anticancer Agents162 topics
- Heterocyclic Compounds162 topics
- Tubulin Inhibitors131 topic
- Vascular Targeting Agents131 topic
- Drug Discovery113 topics
- Molecular Docking102 topics
- Biological Evaluation72 topics
- Synthesis72 topics
- Drug Target Identification61 topic
- Virtual Screening61 topic
- Acetylcholinesterase51 topic
- Cholinesterase Inhibitors51 topic
- Antimicrobial41 topic
- Green Chemistry41 topic
- Multicomponent Reactions41 topic
- Triazines41 topic
- Antimicrobial Activity31 topic
- Click Chemistry31 topic
- Copper-Catalyzed Cycloaddition31 topic
- Quinoxaline31 topic
- Enzyme Regulation21 topic
- Nucleotide Metabolism21 topic
Where does Afzal Nagani work?
Afzal Nagani's main affiliation in the publication record is Parul University, India.
How many publications and citations does Afzal Nagani have?
OpenAlex counts 25 works and 270 citations for Afzal Nagani, an h-index of 9, ranking #2,055,638 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Afzal Nagani. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.